A comparison of the frequency, duration and severity of salivary side effects in differentiated thyroid cancer patients treated with <1.85 GBq (50 mCi) versus 7.4 GBq (200 mCi) I-131 therapy: an analysis of the ThyCa national survey

A comparison of the frequency, duration and severity of salivary side effects in differentiated thyroid cancer patients treated with <1.85 GBq (50 mCi) versus 7.4 GBq (200 mCi) I-131 therapy: an analysis of the ThyCa national survey

Objectives: The salivary side effects (SSE) after high prescribed activity (HPA) of 131I therapy (tx) is well-established; however, the frequency, time of onset, duration and severity of low prescribed activity (LPA) is less well characterized. In this nationwide survey, our objective was to compare...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) 2017-05, Vol.58, p.104
Hauptverfasser: Wu, Di, Gomes Lima, Cristiane Jeyce, Turner, Deniek, Hall, Jordan, Khorjekar, Gauri, Zeymo, Alexander, Brennan, Michael, McIver, Bryan, Bloom, Gary, Van Nostrand, Douglas
Format: Artikel
Sprache:eng
Schlagworte:
Body fluids
Cancer
Comparative analysis
Nuclear medicine
Pain
Patients
Salivary gland
Salivary glands
Side effects
Sjogren's syndrome
Therapy
Thyroid
Thyroid cancer
Xerostomia
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives: The salivary side effects (SSE) after high prescribed activity (HPA) of 131I therapy (tx) is well-established; however, the frequency, time of onset, duration and severity of low prescribed activity (LPA) is less well characterized. In this nationwide survey, our objective was to compare the above parameters of SSE in DTC patients treated with LPA (
ISSN:0161-5505
1535-5667